Befunolol

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584142

CAS#: 39552-01-7 (free base)

Description: Befunolol is a beta blocker with intrinsic sympathomimetic activity used in the management of open-angle glaucoma. It also acts as a β adrenoreceptor partial agonist.


Chemical Structure

img
Befunolol
CAS# 39552-01-7 (free base)

Theoretical Analysis

MedKoo Cat#: 584142
Name: Befunolol
CAS#: 39552-01-7 (free base)
Chemical Formula: C16H21NO4
Exact Mass: 291.15
Molecular Weight: 291.340
Elemental Analysis: Chemical Formula: C16H21NO4 Exact Mass: 291.1471 Molecular Weight: 291.3470 Elemental Analysis: C, 65.96; H, 7.27; N, 4.81; O, 21.97

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 39543-79-8 (HCl)   39552-01-7 (free base)    

Synonym: Befunolol

IUPAC/Chemical Name: 7-(2-Hydroxy-3-(isopropylamino)propoxy)-2-benzofuranyl methyl ketone

InChi Key: ZPQPDBIHYCBNIG-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H21NO4/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14/h4-7,10,13,17,19H,8-9H2,1-3H3

SMILES Code: O=C(C1=CC2=CC=CC(OCC(O)CNC(C)C)=C2O1)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 291.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Koike K, Horinouchi T, Takayanagi I. Comparison of interactions of R(+)- and S(-)-isomers of beta-adrenergic partial agonists, befunolol and carteolol, with high affinity site of beta-adrenoceptors in the microsomal fractions from guinea-pig ciliary body, right atria and trachea. Gen Pharmacol. 1994 Nov;25(7):1477-81. PubMed PMID: 7896063.

2: Maruyama Y, Tanonaka K, Niwa T, Takeo S. Beneficial effects of befunolol on post-hypoxic recovery of cardiac contractility and myocardial metabolism. Arzneimittelforschung. 1992 Dec;42(12):1423-9. PubMed PMID: 1363193.

3: Fusco R, Greco GM, Del Prete A, Caccavale A, Nieto G, Sabbatino S, Santilli F. Long-term effects of befunolol on the corneal endothelium and the consensual ophthalmotonic reaction. Clin Ther. 1992 Nov-Dec;14(6):785-90. PubMed PMID: 1363082.

4: Maruyama Y, Awaji T, Inoue M, Takeo S. Protective effects of befunolol on hypoxic respiration-induced alterations in myocardial energy metabolism of rats. Arzneimittelforschung. 1991 Oct;41(10):1022-6. PubMed PMID: 1799378.

5: Takayanagi I, Hagiwara H, Koike K, Hosokawa T, Kasuya Y. Effects of the R(+)- and S(-)-isomers of beta-adrenoceptor blockers with intrinsic sympathomimetic activity, befunolol and carteolol, on rabbit intraocular pressure. Can J Physiol Pharmacol. 1991 Aug;69(8):1243-5. PubMed PMID: 1685941.

6: Koike K, Hagiwara H, Takayanagi I. Comparison of interactions of R-(+)- and S-(-)-isomers of beta-adrenergic partial agonists, befunolol and carteolol, with high affinity site of beta-adrenoceptors in isolated rabbit ciliary body and guinea-pig taenia caeci. Can J Physiol Pharmacol. 1991 Jul;69(7):951-7. PubMed PMID: 1683268.

7: Maruyama Y, Awaji T, Inoue M, Takeo S. Metabolic profile of beta-adrenoceptor-blocking action of befunolol. Arch Int Pharmacodyn Ther. 1991 May-Jun;311:73-88. PubMed PMID: 1686392.

8: Imamura Y, Nozaki Y, Higuchi T, Otagiri M. Reactivity for prostaglandins and inhibition by nonsteridal anti-inflammatory drugs of rabbit liver befunolol reductase. Res Commun Chem Pathol Pharmacol. 1991 Jan;71(1):49-57. PubMed PMID: 2024065.

9: Höh H. [The local anesthetic effect and subjective tolerance of 0.5% befunolol and 1% pindolol in healthy eyes]. Klin Monbl Augenheilkd. 1990 Apr;196(4):219-24. German. PubMed PMID: 1971855.

10: Dorigo MT, Cerin O, Fracasso G, Altafini R. Cardiovascular effects of befunolol, betaxolol and timolol eye drops. Int J Clin Pharmacol Res. 1990;10(3):163-6. PubMed PMID: 1977708.

11: Takayanagi I, Ogishima M, Koike K. Thermodynamic analysis of beta-adrenergic partial agonists (befunolol and carteolol) interaction with low and high affinity binding sites of beta-adrenoceptors in guinea-pig taenia caecum. Gen Pharmacol. 1990;21(3):303-7. PubMed PMID: 1971246.

12: Takayanagi I, Koike K, Ogishima M. Interactions of R(+) and S(-) isomers of befunolol, a partial agonist with high and low affinity sites of beta-adrenoceptors in guinea-pig taenia caecum. Arch Int Pharmacodyn Ther. 1989 Jul-Aug;300:76-84. PubMed PMID: 2575890.

13: Wegener A, Maierhofer O, Heints M, Hockwin O. Testing a possible cocataractogenic potential of befunolol (Glauconex) with animal cataract models. J Ocul Pharmacol. 1989 Spring;5(1):45-50. PubMed PMID: 2715676.

14: Koike K, Tanaka H, Shigenobu K, Takayanagi I. Binding of [3H]befunolol to beta-adrenoceptors in cardiac muscles of fetal and neonatal rat. Can J Physiol Pharmacol. 1988 Jul;66(7):957-60. PubMed PMID: 2905631.

15: Koike K, Takayanagi I. Interactions of befunolol, a beta-adrenergic partial agonist, and its derivatives with high and low affinity sites in beta-adrenoceptors. J Pharmacobiodyn. 1987 Sep;10(9):494-8. PubMed PMID: 2893834.

16: Koike K, Takayanagi I. A beta-adrenergic partial agonist (befunolol) discriminates two different affinity sites. Jpn J Pharmacol. 1986 Oct;42(2):325-8. PubMed PMID: 2879061.

17: Hayasaka S, Nakazawa M, Mizuno K. Effects of pindolol, befunolol and melanin treated with adrenergic beta-blocking agents on lysosomal enzymes in bovine ciliary body and iris in vitro. Jpn J Ophthalmol. 1986;30(2):185-91. PubMed PMID: 2876118.

18: Takayanagi I, Koike K. A beta-adrenoceptor blocking agent, befunolol as a partial agonist in isolated organs. Gen Pharmacol. 1985;16(3):265-7. PubMed PMID: 2862092.

19: Merté HJ, Stryz JR. [Additional experience with the beta blocker befunolol (Glaukonex) in open-angle glaucoma over a period of 1 year]. Klin Monbl Augenheilkd. 1984 Apr;184(4):316-7. German. PubMed PMID: 6144813.

20: Merté HJ, Stryz JR. [Initial experience with the beta-blocker befunolol in the treatment of open-angle glaucoma in Europe]. Klin Monbl Augenheilkd. 1984 Jan;184(1):55-8. German. PubMed PMID: 6142975.